Invited Participants

ISPOR 13th Patient Representatives Roundtable – Europe
(Supported by Novartis, Pfizer, and Takeda)
Monday, 12 November 2018 – 12:15 – 16:45
Centre de Convencions Internacional de Barcelona
Barcelona, Spain

Patient Representatives:

Nicola Bedlington
Secretary General
European Patients’ Forum (EPF)
Brussels, Belgium

Neil Bertelsen
Chair
HTAi Patient & Citizen Involvement in HTA Interest Group
Berlin, Germany

Anthony Berthon, PharmD
Patient representative
Française de l’Eczema
Les Cotes D’Arey, France

Jan Geissler
Chair, ISPOR Patient Representatives Roundtable - Europe
Co-founder, CML Advocates Network
Board Member, Acute Leukemia Advocates Network
Co-Chair FUTURES Team, EUPATI
CEO, Patvocates
Munich, Germany

Dominique Hamerlijnck
Patient Representative
Lung Foundation Netherlands (Longfonds)
Amersfoort, the Netherlands

Ivett Jakab
Patient advocate
Transplant Foundation
Budapest, Hungary

Joan Jordan
Patient Expert (EUPATI)
Multiple Sclerosis Society of Ireland
Dublin, Ireland

Paola Kruger
Patient Expert (EUPATI)
Accademia dei Pazienti Onlus Advocacy
Rome, Italy
Invited Participants

Robert McBurney, PhD, BSc  
Chief Executive Officer, **Accelerated Cure Project for Multiple Sclerosis**  
Founder and Director, **Optimal Medicine Ltd.**  
Waltham, MA, USA

Derick Mitchell, PhD, BSc. (Hons)  
Chief Executive  
**Irish Platform for Patient Organisations, Science & Industry (IPPOSI)**  
Dublin, Ireland

Kate Morgan  
Policy and Public Affairs Manager  
**Myeloma Patients Europe (MPE)**  
Brussels, Belgium

John Paton  
Ambassador  
**National Rheumatoid Arthritis Society**  
Scotland, United Kingdom

Ananda Plate  
Chair, **WECAN (Workgroup of European Cancer Patient Advocacy Networks)**  
CEO, **Myeloma Patients Europe**  
Munich, Germany

Bettina Ryll, MD, PhD  
Founder, **Melanoma Patient Network Europe (MPNE)**  
Chair, Patient Advocates Working Group, **European Society for Medical Oncology (ESMO)**  
Uppsala, Sweden

Suzanne Schrandt, JD  
Chair, **ISPOR Patient Representative Roundtable – North America**  
Director, Patient Engagement, **Arthritis Foundation**  
Atlanta, GA, USA

Krisztina Kalone Toth  
Patient Representative  
**Collaboration for Health Against Breast Cancer**  
Budapest, Hungary

Mirjami Tran Minh  
Project Manager  
**Association of Cancer Patients in Finland**  
Helsinki, Finland
Invited Participants

**Researcher/Academic**

**Tom Burke**
Senior Health Economist
CHESS study/HCD Economics Ltd.
Manchester, United Kingdom

**Nancy Devlin, PhD**
President-Elect (2019-2020), ISPOR
Director of Research, Office of Health Economics (OHE)
London, United Kingdom

**Karen Facey, PhD**
Honorary Research Fellow and Evidence Based Healthcare Policy Consultant
University of Edinburgh
Edinburgh, United Kingdom

**Sandra Nestler-Parr, PhD, MSc**
Managing Director, Rare Access Ltd.
Trustee, Alpha-1 UK Support Group
London, United Kingdom

**Payer and HTA Stakeholder Participants**

**Margaret Galbraith**
Scientific Project Manager
Haute Autorité de Santé (HAS)
Saint-Denis La Plaine, France

**Claire Gorry, PhD Candidate**
Pharmacist
National Centre for Pharmacoeconomics
Dublin, Ireland

**Heidi Livingstone**
Public Involvement Adviser
National Institute for Health and Care Excellence (NICE)
London, United Kingdom

**Regulatory and Government Participants**

**Nathalie Bere**
Patient Liaison Coordinator
European Medicines Agency (EMA)
London, United Kingdom

**Flora Giorgio, PhD**
Policy Officer, DG Sante
European Commission
Brussels, Belgium
Invited Participants

**Industry Representatives:**
Louise Huneault, BSN, Med  
Head, Patient Relations Hematology, Region Europe  
**Novartis Pharma AG**  
Basel, Switzerland

Judith Luker, BA  
International Alliance Development  
**Pfizer**  
London, United Kingdom

**ISPOR Staff – Lawrenceville, NJ, USA**
Nadia Naaman, Senior Director, Scientific & Health Policy Initiatives  
Theresa Tesoro, MSN, Associate Director, Scientific & Health Policy Initiatives  
Clarissa Coobiall, MPH, CHES, Manager, Scientific & Health Policy Initiatives